Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01107665
Title Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of California, Irvine

skin melanoma


Paclitaxel + Pazopanib

Age Groups: adult
Covered Countries USA

No variant requirements are available.